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Valenzuela and colleagues have recently reviewed some polymorphisms in important candidate genes involved in diﬀerent
pathogenic mechanisms related to preeclampsia (PE) and concluded that various studies in diﬀerent populations have identiﬁed
maternal polymorphisms associated with PE. However, we would like to contribute to some studies regarding candidate genes
related to angiogenesis and endothelial dysfunction in PE performed in the Brazilian population. Speciﬁcally, genotypes and
haplotypes formed by polymorphisms of VEGF, eNOS and MMP-9, along with an example of the interaction among these genes
in the prediction of PE. Our suggestions may provide additional information with clinical relevance to PE susceptibility.
Valenzuela et al. [1] have recently published an interesting
Review Article in a special issue of Journal of Pregnancy dis-
cussing some polymorphisms in important candidate genes
involved in diﬀerent pathogenic mechanisms related to
preeclampsia (PE). They have concluded that various studies
in diﬀerent populations have identiﬁed maternal polymor-
phismsassociatedwithPEthroughcandidategeneapproach-
es [1]. However, some important references from studies
performed in the Brazilian population were not cited, more
speciﬁcally regarding the mentioned candidate genes related
to vascular and endothelial function.
For example, our group has recently demonstrated a
main eﬀect of vascular endothelial growth factor (VEGF)
genotypes and haplotypes involving three clinically relevant
single nucleotide polymorphisms (SNPs) localized in the
promoterregionofVEGF; −2578C/A(rs699947), −1154G/A
(rs1570360), and −634G/C (rs2010963) in the development
of PE, but not with gestational hypertension (GH) [2].
When white and nonwhite pregnant women were consid-
ered together, no signiﬁcant diﬀerences were found in the
distributions of VEGF genotypes or haplotypes (P>0.05).
However, signiﬁcant diﬀerences were found in genotypes
distributions for two VEGF polymorphisms (−2578C/A and
−634G/C; both P<0.05) between the healthy pregnant
(HP) and the PE groups when only white subjects were
considered in the analysis [2]. Importantly, the haplotype
including the alleles −2578C, −1154G, and −634C, which
is associated with higher VEGF gene expression elsewhere
[3], was less common in the PE group compared with the
HP group (P = 0.0047 [2] ) .M o r e o v e r ,w eh a v ep r e v i o u s l y
reportedmarkedinterethnicdiﬀerencesinthedistributionof
these VEGF genotypes and haplotypes [4]. These diﬀerences
could explain why we have found signiﬁcant associations
between VEGF genotypes and one VEGF haplotype with
preeclampsiawhenonlywhitewomenwereconsideredinthe
analysis [2].
Regarding the endothelial nitric oxide synthase (eNOS),
our group had previously examined the association of three
clinically relevant polymorphisms in the promoter region
(−786T/C, rs2070744), in intron 4 (a variable number
of tandem repeats, VNTR) and in exon 7 (Glu298Asp,
rs1799983) of eNOS with PE and GH [5]. No diﬀerences
were observed in the frequencies of genotypes and alleles of
the three polymorphisms among PE, GH, and HP groups
(all P>0.05). However, the haplotype “T Glu a” was more
c o m m o ni nH Pt h a ni nG Ho rP E( 2 0v e r s u s6a n d6 % ,r e s p . ;2 Journal of Pregnancy
P<0.0032). Conversely, the haplotype “C Glu a” was more
c o m m o ni nG Ha n dP Et h a ni nH P( 1 7a n d1 7v e r s u s5 % ;
P = 0.0061). These ﬁndings suggest a contribution of eNOS
haplotypes to the development of hypertensive disorders
of pregnancy (HDP) that is obscured when speciﬁc eNOS
genotypes alone are considered [5].
In addition, we have also examined whether eNOS pol-
ymorphisms and haplotypes aﬀect the responsiveness to
antihypertensive therapy in women with GH or PE [6]. Al-
though we found no signiﬁcant diﬀerences in genotype
or allele distributions when responsive and nonresponsive
groups were compared (both PE and GH; all P>0.05),
eNOS haplotype distribution diﬀered in PE (but not in GH)
responsive and nonresponsive groups (P = 0.0003), thus
suggesting that eNOS haplotypes aﬀect the responsiveness to
antihypertensive therapy in PE [6].
Once PE is associated with decreased nitric oxide (NO)
formation and no previous study had examined whether
eNOS polymorphisms aﬀect this alteration, we hypothe-
sized that NO bioavailability may be modulated by eNOS
polymorphisms in pregnancy [7]. No eﬀects in nitrite
concentrations were found among PE women with diﬀerent
eNOS genotypes and haplotypes (P>0.05). However, the
“C Glu b” haplotype, which was more frequent in the HP
group than in the PE group (20 versus 5; P = 0.0044),
was associated with higher nitrite concentrations than the
other haplotypes in HP (P<0.05). These ﬁndings indicate
that eNOS polymorphisms aﬀect endogenous NO formation
in normal pregnancy, but not in PE and that the “C Glu
b” haplotype may protect against the development of PE by
increasing endogenous NO formation [7].
We would like to contribute to the Review Article of
Valenzuela et al. [1] with our data about another candidate
gene related with angiogenesis. Abnormal production of
matrix metalloproteinases (MMPs), especially MMP-9, may
also play a role in HDP [8, 9]. These alterations may result
from functional polymorphisms in the promoter region of
MMP-9 gene, which are known to change MMP-9 expres-
sion. Therefore, we examined whether the polymorphisms
−1562C/T (rs3918242) and −90(CA)13-25 (rs2234681) in the
promoter of MMP-9 were associated with HDP [8, 9]. The
CT genotype and T allele for the −1562C/T polymorphism,
besides the haplotype including the alleles T and H, were
more commonly found in GH, but not in PE, compared
with the HP group (both P<0.05), suggesting that MMP-
9 polymorphisms may be associated with GH, but not
with PE [8, 9]. In addition, the GH patients with the LH
genotype for the −90(CA)13-25 polymorphism have higher
plasma MMP-9 concentrations than those with other geno-
types [8]. Furthermore, we have examined whether MMP-9
polymorphisms aﬀect the responsiveness to antihypertensive
therapy in women with GH or PE [8]. The T allele for the
−1562C/T polymorphism and the haplotype combining T
and H alleles were associated with lack of responsiveness
to the antihypertensive therapy in GH, and the haplotype
combining C and H alleles was associated with lack of
responsiveness to the antihypertensive therapy in PE [8].
Valenzuela et al. [1] have also pointed out that the
ﬁndings from candidate gene polymorphisms will need to be
complemented by evaluation of interaction between genes.
We have recently provided an example of epistasis in PE
considering the MMP-9 and VEGF polymorphisms [10].
The results from single locus analysis showed signiﬁcant
diﬀerencesinthedistribution ofgenotypesandallelesforthe
VEGF −634G/C polymorphism when PE was compared to
HP and for the MMP-9 −1562C/T polymorphism when GH
was compared to HP, respectively (all P<0.05).Theseresults
are in agreement with our previous ﬁndings [2, 9]. However,
we have observed a signiﬁcant interaction between MMP-
9 and VEGF genes associated with the PE group compared
to HP [10]. The interaction between MMP-9 and VEGF
polymorphisms associated with the PE group is obscured
when speciﬁc genotypes of these single genes are considered,
thus highlighting the importance of gene-gene interactions
as major determinants to complex diseases, including PE
[11].
In conclusion, we consider that the present may con-
tributetotheinterestingreviewarticleofValenzuelaetal.[1].
The ﬁndings and suggestions from our studies on candidate
genes to PE may contribute with additional information of
clinical relevance to PE susceptibility.
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